Longevity Weekly Review 2026-06-10
Week In Review
This was the week that partial cellular reprogramming finally crossed from theory into a human body. On June 9, Life Biosciences announced the first patient had been dosed in its Phase 1 trial of ER-100, a gene therapy that delivers three of the four Yamanaka transcription factors to retinal ganglion cells. The trial targets vision-stealing optic neuropathies, but the larger significance is that an idea drawn directly from the cellular-rejuvenation playbook now has a clinical readout schedule. The capital and infrastructure are arriving at roughly the same pace: longevity startup NewLimit closed a $435 million round led by Founders Fund to begin its own first clinical trial in liver, and Albert Einstein College of Medicine launched BIO-VITAL, a contract-research platform that opens its three aging-research cores to industry partners.
A parallel story dominated the academic side of the field: the maturing science of measuring biological age. In Nature, Tyshkovskiy, Gladyshev, and colleagues introduced universal transcriptomic clocks of mammalian ageing and mortality built from more than 11,000 tissue samples spanning mice, rats, macaques, and humans, with conserved molecular signatures that predict time to death — not just chronological age — and respond to interventions like caloric restriction. A bioRxiv preprint from Hagit Masika, Shmuel Ruppo, and Howard Cedar (now appearing in Nature Communications) sharpens the picture at single-cell resolution, showing that methylation gains at polycomb CpG islands accumulate unevenly cell-to-cell, meaning some cells in the same tissue genuinely age faster than their neighbors. And in a stochastic damage-accumulation analysis from the Alon lab, the team finds that mammals (including humans, dogs, and cats) sit in a “quasi-steady-state” aging regime where damage production and removal stay roughly balanced until late life, while shorter-lived species age “ballistically.”
Several items this week tested whether existing drugs already buy us aging benefits — a “geroscience by repurposing” theme. UC San Diego researchers reported in Nature Communications that semaglutide slowed biological aging by 9% on the DunedinPACE clock in a randomized, placebo-controlled trial of adults with HIV-associated lipohypertrophy, providing the first clinical-trial-grade signal that GLP-1 receptor agonists do more than melt visceral fat. A Nature Aging study showed that metformin restores NCoR1 in the aging primate small intestine, reversing barrier dysfunction and senescence-like phenotypes through a previously unrecognized geroprotective mechanism. Both findings sharpen a question the field will need to answer soon: are GLP-1s and metformin already longevity drugs we just haven’t labeled as such?
The week also showed longevity moving into the cultural mainstream. Harvard Health Publishing released “Pathways to Longevity”, the institution’s first consumer-facing report on geroscience, biological age, and emerging interventions like senolytics, rapamycin, metformin, and GLP-1 drugs — a watershed for the field’s legitimacy outside specialist circles. Coverage of Florida’s biological-age-testing boom showed the same trend on the consumer side: aging clocks of the kind academics are still validating are already being sold in clinics and concierge wellness practices. The throughline of the week is convergence — better measurement, real clinical milestones, repurposable drugs with measurable signals, and a public ready to listen.
Items
First Patient Dosed in Phase 1 Trial of Life Biosciences’ Epigenetic Reprogramming Therapy
Life Biosciences announced on June 9 that the first participant has been dosed in the Phase 1 clinical trial of ER-100, a gene therapy designed to rejuvenate retinal ganglion cells in patients with vision-stealing optic neuropathies. The trial targets two indications — open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) — that share a common pathology: damaged or dysfunctional retinal ganglion cells for which current treatments address only upstream risk factors like intraocular pressure rather than the cell damage itself.
ER-100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform and the first partial epigenetic reprogramming therapy to reach human trials. It uses an adeno-associated virus vector to deliver three of the four Yamanaka transcription factors — OCT4, SOX2, and KLF4 — to target cells, where their controlled expression is intended to reset methylation patterns toward a younger configuration without inducing the cells to lose their differentiated identity. The fourth factor, c-Myc, is excluded specifically to lower the risk of uncontrolled growth and tumor formation.
The conceptual basis is that aging is driven in significant part by accumulated changes in epigenetic information — the marks layered on top of DNA that tell each cell which genes to read — rather than by irreversible damage to the genetic code itself. If true, those marks can in principle be reset, and the cell can recover lost function. The Phase 1 trial is primarily evaluating safety and tolerability, with secondary endpoints assessing visual function. Initial readouts are expected by late 2026 or early 2027.
A successful safety signal would be a meaningful inflection point. Partial reprogramming has been the most-discussed mechanism in the longevity field since the original Sinclair-lab vision-restoration paper in 2020, and ER-100 is the first time the approach is being tested directly in humans. Even modest signals will shape how the field thinks about delivery routes, dose-response, and which indications come next.
Source: Life Biosciences
Universal Transcriptomic Hallmarks of Mammalian Ageing and Mortality
A new Nature paper from Alexander Tyshkovskiy, Vadim Gladyshev, and colleagues, published June 4, introduces “transcriptomic clocks” of aging built from RNA-sequencing data — gene-expression measurements — across more than 11,000 tissue samples spanning four mammalian species: mouse, rat, macaque, and human. Unlike the dominant methylation-based clocks that primarily estimate chronological age, these clocks are explicitly trained to predict mortality risk and a normalized lifespan position, then validated against intervention data.
The team identified conserved transcriptomic signatures of aging that hold across species and cell types. Genes related to cellular senescence, inflammation, and apoptosis go up with age; genes related to wound healing, cell differentiation, and extracellular matrix synthesis go down. These are not new individually, but the cross-species robustness of the signature is striking — it suggests there is a shared molecular core of mammalian aging that interventions can be benchmarked against. The authors built pathway-specific “module clocks” that read aging within distinct systems — inflammation, mitochondrial metabolism, chromatin regulation, extracellular matrix — opening the door to interventions tuned to specific failure modes.
Critically, the biomarkers are responsive: the clocks register the effects of caloric restriction and other lifespan-extending interventions in mice, and they predict time to death in humans. That responsiveness is exactly what the field has needed. Most published aging biomarkers can describe aging but cannot reliably tell you whether a treatment is working over a tractable time horizon.
The team released a web tool called TACO (Transcriptomic Age Calculator Online) so other researchers can apply the clocks to their own RNA-sequencing datasets. Expect rapid uptake: any group with a banked tissue collection now has a way to ask whether their candidate intervention shifts the deep, conserved aging signature, not just one peripheral marker.
Source: Nature
Metformin Restores NCoR1 and Delays Aging in the Primate Small Intestine
A Nature Aging study published June 9 used single-nucleus RNA sequencing on small intestine tissue from aging nonhuman primates and identified barrier dysfunction, chronic inflammation, and a shift in stem cell fate — away from absorptive enterocytes and toward secretory lineages — as conserved features of intestinal aging. At the molecular core of these changes, the authors converged on a single transcriptional corepressor: NCoR1, whose levels decline with age in both primate and human gut tissue.
Knocking down NCOR1 in human intestinal epithelial cells and organoids recapitulated the aging phenotypes — senescence, disrupted tight junctions, lineage imbalance — while overexpressing it alleviated them. The strongest translational finding: metformin treatment in nonhuman primates restored NCoR1 levels and delayed multiple intestinal aging phenotypes, providing a previously unknown mechanism for the diabetes drug’s much-debated geroprotective effects.
This matters for several reasons. First, the gut is one of the most rapidly turning-over tissues in the body and a major source of inflammatory signals that drive systemic aging — fixing intestinal aging may have outsized whole-body benefits. Second, NCoR1 is now a well-defined drug target with a known regulator already in widespread clinical use. Third, the study lends molecular substance to the broader case for evaluating metformin as a geroprotective drug in humans, complementing ongoing trials like TAME.
The work is also a clean demonstration of the methodological shift now underway in aging research: single-cell and single-nucleus methods, applied to nonhuman primates with multi-year aging trajectories, are producing the kind of conserved targets that translate. Pharmacological NCoR1 enhancers are the obvious next chapter.
Source: Nature Aging
Semaglutide Slows Biological Aging in a Randomized Controlled Trial
Researchers at UC San Diego and partner institutions, publishing in Nature Communications on June 2, reported the first randomized, placebo-controlled clinical evidence that semaglutide — the active ingredient in Ozempic and Wegovy — slows biological aging as measured by epigenetic clocks. The analysis used previously collected data from a 108-person trial in adults with HIV-associated lipohypertrophy, a condition in which excess fat accumulates around the abdomen.
The headline number: semaglutide reduced the pace of biological aging by 9% on the DunedinPACE clock, one of the most validated second-generation epigenetic clocks. The drug also produced improvements on PCGrimAge, a clock optimized to predict mortality and age-related disease, along with broader signals across clocks tuned to inflammation, brain, heart, kidney, liver, blood, and metabolic aging.
The proposed mechanisms tie several threads together. GLP-1 receptor agonists reduce systemic and chronic immune-activation-driven inflammation — a primary driver of accelerated aging in people with HIV — while also lowering visceral fat, improving insulin sensitivity, and possibly altering gene expression in multiple organ systems. The lead researcher was careful to caveat the finding: “We are not saying that semaglutide reverses aging or makes people younger. What we are seeing is a signal that it may slow some of the biological processes associated with aging.”
The implications are large. GLP-1 receptor agonists are already among the most prescribed drugs in the world, with millions of people taking them for obesity and diabetes. If even a fraction of the biological-age signal translates into reduced incidence of age-related disease, the population-health effect could rival historical interventions like statins. Larger trials in non-HIV populations and over longer durations will be needed to confirm and generalize the effect.
Source: UC San Diego Today
NewLimit Raises $435 Million Ahead of First Clinical Trial
NewLimit, the longevity startup co-founded by Coinbase CEO Brian Armstrong, announced a $435 million Series C financing round on June 2, led by Founders Fund and joined by Thrive Capital, Lilly Ventures, and tech investors Nat Friedman and Daniel Gross. The round values the company at approximately $3.1 billion and funds its push into the clinic with a first liver-targeted therapy expected to enter human trials.
NewLimit’s approach is to identify combinations of transcription factors that can partially reprogram aged cells toward a younger transcriptional state — a more pharmacologically tractable version of the broader cellular-rejuvenation thesis that has animated the field since the Yamanaka factor work. The company has been unusually open about its computational stack, publishing on machine-learning-driven transcription-factor screening and on the use of large-scale single-cell measurements to map cellular states. The liver was chosen as a first indication because of its central role in metabolic health, its substantial regenerative capacity, and the relatively well-characterized epigenetic and transcriptional drift that accompanies hepatic aging.
The deal is one of the largest single funding rounds in longevity biotech history and signals that, despite the broader biotech downturn, late-stage investors are willing to write large checks for companies that have advanced from platform development into concrete clinical pathways. Founders Fund’s lead position — and the involvement of Eli Lilly’s venture arm — points to growing institutional pharma interest in the space.
For the broader field, the round is meaningful as evidence that the cellular rejuvenation thesis is graduating from billionaire-funded basic science into the kind of disciplined, execution-stage biotech work that produces approved drugs. The question now is whether NewLimit’s clinical readouts in the next 18-24 months will validate the broader bet.
Source: STAT News
Albert Einstein College of Medicine Launches BIO-VITAL Gerotherapeutics Program
Albert Einstein College of Medicine announced the launch of BIO-VITAL — the Batia and Idan Ofer program for Validation of Interventions Targeting Aging and Longevity — a new initiative housed within Einstein’s Institute for Geroscience that opens the institution’s aging-research capabilities to biotech and pharmaceutical partners. The program is supported by the Ofer Family Foundation.
BIO-VITAL is organized around three integrated research cores. The Cellular Aging & Technology Core, directed by Ana Maria Cuervo, M.D., Ph.D. — one of the world’s leading autophagy researchers — provides assays for cellular hallmarks of aging including autophagy, proteostasis, senescence, and mitochondrial dysfunction. The Preclinical Aging Models Core, directed by Derek Huffman, Ph.D., offers proprietary animal models for evaluating gerotherapeutic candidates. The Human Longevity Multi-omics Core, led by Nir Barzilai, M.D. (principal investigator of the TAME metformin trial) and Sofiya Milman, M.D., M.S., brings access to data and biospecimens from the longest-running cohorts of healthy centenarians and their offspring.
In total, BIO-VITAL provides more than 30 assays and services covering drug screening, biomarker discovery, and translational strategy. The model is significant: aging research has historically been an academic preserve, with industry partners reinventing capabilities at considerable expense. By packaging Einstein’s tools and datasets — including the LonGenity and Longevity Genes Project cohorts — into a contract-research-style platform, BIO-VITAL substantially lowers the cost and time required for a pharma or biotech program to evaluate a candidate gerotherapeutic.
The launch reflects a broader maturation of the field. Geroscience has accumulated enough validated targets, biomarkers, and animal models that the bottleneck is no longer scientific consensus but industrial translation. Initiatives like BIO-VITAL aim directly at that bottleneck.
Source: BioSpace
Cell-to-Cell Methylation Variability as a Hallmark of Aging
A study from Hagit Masika, Shmuel Ruppo, and Howard Cedar at the Hebrew University, now appearing in Nature Communications (and previously available as a bioRxiv preprint), uses single-cell methylation profiling to show that aging is not a uniform process within tissues — even genetically identical neighboring cells diverge significantly in their epigenetic state as they age.
The team focused on methylation at polycomb CpG islands, genomic regions that normally remain unmethylated and that lose this protected status with age. By tracking individual cells, they found that the gain of methylation at these sites does not accumulate evenly across a tissue but instead concentrates unevenly — some cells acquire substantially more methylation than others. The variation is large enough that, in effect, some cells in the same tissue age faster than their neighbors.
This is a significant conceptual refinement of the standard “epigenetic clock” picture, which has been derived almost entirely from bulk-tissue measurements that average over millions of cells. If individual cells age at very different rates, then a bulk measurement may understate the depth of aging in a tissue while still flagging meaningful trends. It also has direct therapeutic implications: senolytic-style strategies that selectively clear the worst-aged cells might be far more effective per cell removed than is currently appreciated, because the worst-aged cells are not the average.
The work fits into a broader push to understand cellular heterogeneity in aging tissues. Combined with the universal transcriptomic clock results published the same week, the field is converging on a picture in which aging is both deeply conserved in its molecular signature and highly heterogeneous in how it manifests within individual cells.
Source: bioRxiv
A Damage Accumulation Model Reveals Two Distinct Aging Regimes Across Species
A new study from the Uri Alon lab (Raz, Yang, and Alon) fits species-level survival data to a stochastic model in which damage accumulates and is removed at parameter-specified rates, and asks which parameters explain why lifespans differ by seven orders of magnitude across species. The headline conclusion is that the damage production rate — not the removal rate, not the threshold for death, not the noise amplitude — is what almost entirely drives interspecies lifespan variation.
That alone is striking: across yeast, worms, flies, mice, dogs, cats, and humans, the model finds that the timescale on which damage is cleared from cells is remarkably similar, on the order of a day. Lifespans differ because some species generate damage extraordinarily quickly while others generate it slowly. Within this framework, the team identifies two qualitatively different aging regimes. Yeast, nematodes, flies, and mice age “ballistically” — damage production runs faster than removal, and damage piles up in a roughly linear-in-time trajectory. Humans, dogs, and cats age “quasi-steady-state” — damage production and removal are nearly balanced for most of life, with mortality rising only when the balance finally tips.
The practical implication: interventions targeting damage removal may have very different effects in mice (whose aging is removal-saturated) than in humans (where removal is already mostly keeping up). The model gives a quantitative argument for why mouse-lifespan extensions sometimes fail to translate to humans, and conversely for why interventions that reduce damage production could be especially potent in long-lived species.
The work fits with a recent trend toward minimal-mechanistic models that explain a great deal of aging phenomenology with very few parameters. It complements descriptive multi-omic work like the universal transcriptomic clocks by offering a generative theory of why those signatures arise.
Source: Research Square
Harvard Health Publishing Releases “Pathways to Longevity”
Harvard Health Publishing, the publishing arm of Harvard Medical School, released “Pathways to Longevity” — its first consumer-facing special report dedicated to longevity science — late in May, with coverage reverberating through the first week of June. The report introduces general readers to geroscience concepts that have largely been confined to specialist circles: healthspan vs. lifespan, biological age, the hallmarks of aging, inflammaging, and emerging therapeutic categories including senolytics, rapamycin, metformin, and GLP-1 receptor agonists.
The report’s medical editor is David Barzilai, a longevity physician affiliated with Harvard Medical School. It evaluates not only emerging interventions but also the more familiar territory of dietary patterns (with measured plant-based emphasis), exercise, sleep, alcohol, and supplement evidence — including a notably skeptical take on most supplement claims. It also engages directly with the Blue Zones literature, which has come under increasing scientific scrutiny, while presenting it as one data point rather than a prescription.
The significance is less in any single piece of advice and more in the institutional gesture. A major academic medical institution publishing a structured, evidence-graded primer on longevity medicine for the general public legitimizes a field that has long struggled with the perception that it was the preserve of either basic researchers or wealthy biohackers. As Barzilai put it: “A major academic medical institution is introducing the public to the conceptual framework of longevity medicine in an evidence-based way.”
Coverage emphasized polling data showing that 76% of U.S. adults want to reach age 80 and 29% hope to reach 100 — a demand signal that the report explicitly takes seriously. Expect copycat reports from peer institutions over the next 12-18 months as longevity continues its transition into a mainstream preventive-medicine discipline.
Source: Lifespan.io
Biological-Age Testing Goes Mainstream in Florida
A widely syndicated report in early June documented the rapid spread of biological-age testing and “reverse-aging” clinics across Florida, where concierge wellness practices and longevity-focused medical groups have begun marketing the same epigenetic clocks and proteomic panels that academic researchers are still validating. The trend captures the growing gap between what consumers are buying and what the underlying science can yet support.
University of Florida researchers featured in the coverage focus on “brain age” estimates derived from MRI and lifestyle data, with their work suggesting that healthy habits — regular aerobic exercise, restorative sleep, stress management, optimism, social support — can shift brain age estimates by up to eight years versus chronological expectations. That is an academically interesting result; it is also a result that consumer clinics are quick to translate into branded “brain age reversal” packages.
The phenomenon has two faces. The optimistic read is that consumer demand for biological-age measurement is creating an unprecedented data flywheel: clinics generating tens of thousands of methylation profiles, proteomic panels, and brain-age MRI scans every month, much of which feeds back into research datasets that improve the underlying clocks. The cautious read is that biological-age estimates remain noisy, modestly reproducible, and only weakly responsive to most lifestyle changes over short timescales — and that consumers paying for serial tests may be over-reading short-term fluctuations.
What is unambiguous is that longevity has crossed a threshold of cultural attention. Coverage of consumer biological-age testing in mainstream wellness sections — adjacent to the Harvard Health Publishing report and the broader celebrity-tied Bryan Johnson cultural moment — confirms that the field has moved beyond specialist conversation. The challenge for the science is to keep pace with the demand without sacrificing rigor.
Source: The Detroit News